Background: Carcinoma of prostate is one of common tumors of old age in men. With digital rectal examination (DRE) prostate-specific antigen (PSA) is a major screening tool for prostate cancer. While Trans Rectal Ultra Sound (TRUS)-guided needle biopsies of prostate are considered gold standard for the diagnosis of prostate cancers.
Prostate cancer is the leading cause of new cancer in men and is second only to lung cancer as a leading cause of cancer-related deaths in men. [4] Prostate cancer is the most common cancer of men in USA and 10th common malignancy in India. [1, 2] Several factors, including age, race, family history, hormone levels, and environmental influences are suspected to play a role in pathogenesis. [5] Because of the location of prostate gland at bladder neck, enlargement of the gland leads to problems related to urinary obstruction. [16] The incidence of prostatic diseases, benign prostatic hyperplasia, and carcinoma increases with age.
Introduction
Prostatic carcinoma is an important growing health problem, presenting a challenge to urologists, radiologists and pathologist.
[1,2] The incidence of prostatic diseases, benign prostatic hyperplasia, and carcinoma increases with age. [3] 2017. 2017 of biological behavior and influential factors used in determining treatment. PSA, when combined with Gleason score and clinical stage, improves the prediction of pathological stage for prostate carcinoma. [5] The present study includes description of incidence of various lesions of prostate, their clinical manifestations, serum PSA level, classification, and grading of prostate tumors.
The diagnosis requires careful history, physical examination including digital rectal examination (DRE), serum PSA estimation and transrectal ultrasound (TRUS), and TRUSguided needle biopsies of the prostate.
Among these, the latter are considered the gold standard for the tissue diagnosis of the prostatic cancer. To correlate the serum PSA level findings with histopathological diagnosis. [6] Aim and Objectives • To determine the age distribution of patients with prostatic lesion.
• To study prevalence of distribution of various prostatic lesions, admitted in Civil Hospital, Ahmedabad.
• To determine histological types related with PSA.
Material and Methods

Patients
The present study was carried out at the Department of Histopathology, B.J.M.C., Civil Hospital Ahmedabad, from January 2015 to October 2015. The study included 110 cases between 50 and 76 years of age group, who presented to with or without complaints of prostatism. Their detailed physical examination and DRE were performed, followed by appropriate laboratory investigations including determination of serum PSA. Serum PSA levels were calculated and correlated with various clinical and biopsy findings.
Biopsy Technique
TRUS-guided needle biopsies of the prostate gland were performed only in those patients who had serum PSA levels ≥ 4 ng/ml and/or abnormal DRE suspicious for prostate cancer. Ultrasound guidance was provided by a diagnostic ultrasound machine with, biplaner transrectal probe. Biopsies were obtained with patient in right or left lateral decubitus position and the prostate was imaged in the sagittal plane. [7, 8] Only first time biopsies were included. Repeat biopsies were not included in the analysis.
Pathologic Study
The biopsy specimens were processed and studied at the Department of Histopathology, B.J.M.C. Gross examination of the biopsies included precise length and diameter and color of the cores. The biopsies were processed for paraffin embedding, cut at 3-5 µm and stained by hematoxylin and eosin (H&E) for detailed microscopic examination.
The histopathological grading and scoring by Gleason system was carried out in all cases of adenocarcinoma of prostate, criteria for the grading and scoring of needle biopsies of the prostate. [10] 
Statistical Analysis
Simple descriptive statistics such as mean ± SD were used for continuous variables such as age and clinical and laboratory parameters.
Percentages were used for categorical data.
Results
The main clinical features of all patients are shown in Table 1 in variable combination.
In the present study, the mean age of all patients was 66.9 ± 9.4 years. Out of 110 cases, 69 (62.72%) cases showed benign lesions with mean age 57.7 ± 4.86 years and 41 (37.2%) were malignant with mean age 65.70 ± 5.64 years ( Table 2) .
Out of 110 cases, 41 (37.2%) revealed adenocarcinoma and the remaining 69 (62.72%) showed adenomyomatous hyperplasia (Figure 1 ) with or without associated active prostatitis ( Figure 2 , Table 3 ). Six patients with chronic granulomatous inflammation showed no caseation necrosis and negative results for acid fast bacilli on Ziel-Nelson staining and thus were labeled as idiopathic granulomatous prostatitis (Figure 3) .
The mean serum PSA value was 13.36 ± 8.6 ng/ml; total range was 4-36 ng/ml. The mean PSA was significantly higher in the cancer group than in the benign. The rate of cancer detection increased significantly with the increase in serum PSA level. Briefly, 21 out of 110 patients (19.09%) had serum PSA ≥ 20.1 ng/ml. Of these, 17 (80.95%) patients had prostatic adenocarcinoma, and 4 (19.04%) benign changes (Table 4) .
Raised serum PSA level were arbitrarily divided into mild (≥ 4-10 ng/ml), moderate (≥ 10.1-20 ng/ml), and marked elevations (≥ 20.1 to highest) ( Table 5) . 
Discussion
Carcinoma of prostate is common cancer in India because of increasing life expectancy and relatively better diagnostic method. The gold standard triad for diagnosing prostate cancer comprised DRE, PSA level, and transrectal ultrasonography. [11] It is a report on the spectrum of pathological lesions found in TRUS-guided biopsies of the prostate in men with elevated serum PSA and/or symptoms of prostatism from B.J.M.C., Ahmedabad.
In the present study, mean age of all patients was found 66.9 ± 9.4 years. Out of 110 cases, 69 cases (62.72%) cases showed benign prostatic lesions with mean age 57.7 ± 4.86 years and 41 cases (37.2%) malignant lesions with mean age 65.70 ± 5.64 years. Briefly, 21 out of 110 patients (19.09%) had serum PSA ≥ 20.1 ng/ml. Of these, 17 (80.95%) patients had prostatic adenocarcinoma, and 4 (19.04%) benign changes which indicate that marked raised serum PSA level was found in malignant prostatic lesions. In our study, most patients were symptomatic; 92% presented with lower urinary tract symptoms (LUTS) commonly known as prostatism. Very few patients (8%) presented for screening of the prostate level > 10 ng/ml, in study by Khitij et al [18] malignant prostatic lesions were 63.7%, in study by Mwalyoma et al [19] malignant lesions were 94.7%, in study of Sladana Zivkovic et al [20] study malignant lesions were 70.0%. In the present study with marked raised serum PSA level were found in 75.60% which was comparable with other studies. This is an interesting finding which shows that patients with markedly elevated serum PSA levels are more likely to harbor adenocarcinoma in their biopsies than benign changes, as in previous studies [6] (Table 6 ). Serum PSA determination has certain limitations for the diagnosis of prostate cancer. Serum PSA levels are slightly elevated in cases of BPH because of prostate tissuespecific protease property of PSA. In a significant number of patients with raised serum PSA, TRUS-guided biopsies showed benign hyperplastic or inflammatory lesions rather than cancer. The proportion of benign lesions was greater in patients with mild or moderate elevations of serum PSA. In contrast, cancer was more frequent in cases with marked elevations in serum PSA.
Conclusion
In the present study, the commonest pathology encountered in the prostates studied was benign lesion (62.72%). Incidence of carcinoma was 41 cases (37.2%). Briefly, 69 (62.72%) cases showed benign lesions with mean age 57.7 ± 4.86 and 41 (37.2%) were malignant with mean age 65.70 ± 5.64. In TRUS biopsies of prostate in patients with symptoms of prostatism and high serum PSA, the mean serum PSA was 24.63 ± 9.4 ng/ml in adenocarcinoma. In benign prostatic lesion mean serum PSA level was 6.16 ± 2.4 ng/ml. In the present study serum PSA level are the most useful front line methods for assessing and individual's risk of prostate cancer. In addition elevated level more than 4.0 ng/ml with TURS-guided needle biopsy is most useful and accurate diagnostic method for prostate.
cancer at asymptomatic stage. This is understandable given the low level of awareness of this cancer among the general population.
In a study from China, cancer detection rate was 40%. [6] In the study by Levine et al [13] cancer was detected in 31% of cases. Presti et al [14] observed prostate cancer in 42% of the TRUS-guided biopsies. All these studies included patients with raised serum PSA associated with or without prostatism, as in our study. However, different levels of serum PSA and different biopsy strategies were employed in these studies, which are reflected in slight differences in cancer detection rates. The overall cancer detection rate in TRUS-guided biopsies in our series was 37.2%. Marked raised serum PSA 
